Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07660783 · ClinicalTrials.gov registry record · Phase 2
Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant Diseases
A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
- Not yet
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT07660783: Clinical Trial Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
NCT07660783 is a Phase 2 study that has not yet begun recruiting, run by Fred Hutchinson Cancer Center. The registered enrollment target is 40 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07660783, a Phase 2 study, has not yet begun recruiting, sponsored by Fred Hutchinson Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This phase II trial investigates how well a naive T cell depleted graft work for the reduction of graft versus host disease in patients with non-malignant diseases requiring hematopoietic cell transplantation. Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient's immune cells and help destroy any remaining cancer cells.
Primary Outcome
Free of grade III-IV acute and NIH chronic (moderate-severe) GVHD requiring systemic immunosuppression
Interventions
- BIOLOGICAL ALLOGENEIC CD34+ ENRICHED AND CD45RA- DEPLETED PBSCs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-09 |
| Est. Completion | 2035-09 |
| Phase | Phase 2 |
What is known before NCT07660783 opens enrollment
NCT07660783 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 1 intervention - of which ALLOGENEIC CD34+ ENRICHED AND CD45RA- DEPLETED PBSCs is the first listed.
NCT07660783 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07660783 about?
NCT07660783 is a clinical study titled "Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant Diseases". This phase II trial investigates how well a naive T cell depleted graft work for the reduction of graft versus host disease in patients with non-malignant diseases requiring hematopoietic cell transplantation. Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell t...
What is the current status of trial NCT07660783?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2026-09. Estimated completion is 2035-09.
What interventions are being tested in trial NCT07660783?
The interventions under investigation include: ALLOGENEIC CD34+ ENRICHED AND CD45RA- DEPLETED PBSCs (BIOLOGICAL).
Who is sponsoring clinical trial NCT07660783?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07660783's enrollment target sits among peer trials
40 1362nd of 2000 higher than 542 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia